S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom

Adicet Bio (ACET) Stock Price, News & Analysis

$2.27
+0.08 (+3.65%)
(As of 04/17/2024 ET)
Today's Range
$2.22
$2.35
50-Day Range
$1.95
$3.38
52-Week Range
$1.10
$7.50
Volume
760,768 shs
Average Volume
691,379 shs
Market Capitalization
$186.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.83

Adicet Bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
465.3% Upside
$12.83 Price Target
Short Interest
Bearish
9.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$7.50 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.72) to ($1.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

Medical Sector

499th out of 913 stocks

Pharmaceutical Preparations Industry

224th out of 420 stocks

ACET stock logo

About Adicet Bio Stock (NASDAQ:ACET)

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

ACET Stock Price History

ACET Stock News Headlines

Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update
ACET Adicet Bio, Inc.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Adicet Bio’s Promising Drug Pipeline and Buy Rating Justification
JMP Securities Keeps Their Hold Rating on Adicet Bio (ACET)
ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023
Adicet Bio: Q4 Earnings Insights
Adicet Bio, Inc Q4 loss drops in line with estimates
7 Top-Tier Penny Stocks for a Smart Bet
ACET Apr 2024 7.500 call
See More Headlines
Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/17/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Trading Companies & Distributors
Current Symbol
NASDAQ:ACET
CUSIP
00444610
CIK
2034
Fax
N/A
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.83
High Stock Price Target
$27.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+465.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-142,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$24.99 million
Book Value
$2.43 per share

Miscellaneous

Free Float
57,919,000
Market Cap
$186.53 million
Optionable
Optionable
Beta
1.88
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Chen  Schor BAMr. Chen Schor BA (Age 52)
    CPA, M.B.A., CEO, President & Director
    Comp: $899.58k
  • Dr. Aya Jakobovits Ph.D. (Age 68)
    Founder & Independent Director
    Comp: $40k
  • Dr. Blake Aftab Ph.D. (Age 43)
    Senior VP & Chief Scientific Officer
    Comp: $675.04k
  • Dr. Francesco Galimi M.D. (Age 56)
    Ph.D., Chief Medical Officer & Senior VP
    Comp: $680.37k
  • Mr. Brian Nicholas Harvey (Age 63)
    Chief Financial Officer
    Comp: $596.79k
  • Dr. Donald Healey Ph.D. (Age 62)
    Chief Technology Officer
  • Ms. Amy Locke
    Chief Human Resource Officer
  • Dr. Nancy L. Boman M.D.
    Ph.D., Senior VP & Chief Regulatory Officer

ACET Stock Analysis - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACET shares.
View ACET analyst ratings
or view top-rated stocks.

What is Adicet Bio's stock price target for 2024?

8 Wall Street analysts have issued 1 year price objectives for Adicet Bio's shares. Their ACET share price targets range from $5.00 to $27.00. On average, they expect the company's stock price to reach $12.83 in the next year. This suggests a possible upside of 465.3% from the stock's current price.
View analysts price targets for ACET
or view top-rated stocks among Wall Street analysts.

How have ACET shares performed in 2024?

Adicet Bio's stock was trading at $1.89 on January 1st, 2024. Since then, ACET stock has increased by 20.1% and is now trading at $2.27.
View the best growth stocks for 2024 here
.

Are investors shorting Adicet Bio?

Adicet Bio saw a increase in short interest in March. As of March 31st, there was short interest totaling 7,690,000 shares, an increase of 32.4% from the March 15th total of 5,810,000 shares. Based on an average daily trading volume, of 1,690,000 shares, the short-interest ratio is currently 4.6 days.
View Adicet Bio's Short Interest
.

When is Adicet Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ACET earnings forecast
.

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) announced its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.03.

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACET) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners